What is Rhaeos?
Rhaeos, Inc. is a private, clinical stage medical device company that emerged from Northwestern University's John A. Rogers Research Group. The company is dedicated to developing wearable sensors designed to enhance the care of patients managing chronic and complex conditions. Its flagship product, the FlowSense noninvasive wireless sensor, aims to address a critical unmet need in the management of hydrocephalus. The company's development has been supported by grants from prestigious institutions such as the National Institute of Health and the National Science Foundation, alongside funding from various pediatric foundations and consortia.
How much funding has Rhaeos raised?
Rhaeos has raised a total of $12.7M across 2 funding rounds:
Angel/Seed
$2.2M
Series A
$10.5M
Angel/Seed (2021): $2.2M with participation from Lateral Capital, Creative Ventures, and Portal Innovations
Series A (2023): $10.5M led by Lateral Capital, Steele Foundation for Hope, and Creative Ventures
Key Investors in Rhaeos
Lateral Capital
Lateral Capital is a mission-driven venture fund that partners with entrepreneurs building essential digital infrastructure, particularly in Africa. They provide flexible and patient capital from Seed to Growth stages, combining debt and equity.
Creative Ventures
Creative Ventures is a venture capital firm focused on identifying and investing in companies with deployable solutions to critical global challenges. They emphasize a market-first approach, investing in scalable technologies that meet existing demand.
Portal Innovations
Portal Innovations is a venture development engine and venture capital firm specializing in early-stage biotech and medtech startups. They offer capital, lab spaces, and strategic funding to foster company growth.
What's next for Rhaeos?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for Rhaeos. This capital infusion is expected to accelerate the company's product development pipeline, potentially enabling Rhaeos to advance its FlowSense sensor through further clinical trials and regulatory approvals. The focus on hydrocephalus patients suggests a strategic move into a specialized segment of the medical device market. Future growth will likely involve scaling manufacturing capabilities, expanding the commercial team, and potentially exploring partnerships to broaden market access and patient reach.
See full Rhaeos company page
